{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:26:21Z","timestamp":1790803581974,"version":"4.1.0"},"reference-count":26,"publisher":"The Endocrine Society","issue":"9","license":[{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"vor","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Anaplastic thyroid cancer (ATC) is an aggressive and lethal malignancy with limited therapeutic options and poor prognosis. In recent years, the therapeutic arsenal of locally advanced or metastatic ATC has been expanded, with V-Raf murine sarcoma viral oncogene homolog B (BRAF)\/mitogen-activated protein kinase kinase-MAPKK (MEK) inhibitors for the subset of BRAF V600E-mutant ATC. For BRAF wild-type ATC and without other actionable alterations, the most promising strategy is certainly immune checkpoint inhibitors, which have shown activities both in monotherapy or in combination regimens. However, access to novel treatments is heterogeneous worldwide for ATC patients, and activity of immunotherapy as a single agent is limited.<\/jats:p>\n                  <jats:p>We report the case of a patient with locally advanced BRAF wild-type ATC who achieved a near-complete and durable response following a multimodal treatment approach combining chemotherapy (carboplatin and paclitaxel), immunotherapy (pembrolizumab), and external beam radiotherapy. Pembrolizumab monotherapy was continued as maintenance therapy, and disease control was maintained for over 1 year.<\/jats:p>\n                  <jats:p>This case highlights the potential efficacy of chemo-immunotherapy in BRAF wild-type ATC, especially when a rapid tumor reduction is required. It supports the use of immune checkpoint inhibitors combined with cytotoxic agents as a viable therapeutic option in this aggressive tumor subtype.<\/jats:p>","DOI":"10.1210\/jcemcr\/luaf160","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T08:04:14Z","timestamp":1750838654000},"source":"Crossref","is-referenced-by-count":4,"title":["Remarkable Response to Chemo-immunotherapy In Anaplastic Thyroid Cancer"],"prefix":"10.1210","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-2979-6495","authenticated-orcid":false,"given":"Francesca","family":"Carosi","sequence":"first","affiliation":[{"name":"Department of Medical and Surgical Sciences, University of Bologna , Bologna 40138 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Concetta","family":"Nigro","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, University of Bologna , Bologna 40138 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giambattista","family":"Siepe","sequence":"additional","affiliation":[{"name":"Radiation Oncology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna , Bologna 40138 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Repaci","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Diabetes Prevention and Care, IRCCS Azienda Ospedaliero-Universitaria di Bologna , Bologna 40138 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura Deborah","family":"Locati","sequence":"additional","affiliation":[{"name":"Internal Medicine and Therapeutics Department, University of Pavia , Pavia 27100 ,","place":["Italy"]},{"name":"Medical Oncology Unit, Istituti Clinici Scientifici Maugeri IRCCS , Pavia 27100 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2103-1960","authenticated-orcid":false,"given":"Margherita","family":"Nannini","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, University of Bologna , Bologna 40138 ,","place":["Italy"]},{"name":"Medical Oncology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna , Bologna 40138 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"issue":"9","key":"2025081304271013000_luaf160-B1","first-page":"5888","article-title":"The incidence and survival analysis for anaplastic thyroid cancer: a SEER database analysis","volume":"11","author":"Lin","year":"2019","journal-title":"Am J Transl Res"},{"issue":"3","key":"2025081304271013000_luaf160-B2","doi-asserted-by":"crossref","first-page":"113826","DOI":"10.1016\/j.celrep.2024.113826","article-title":"The genomic and evolutionary landscapes of anaplastic thyroid carcinoma","volume":"43","author":"Zeng","year":"2024","journal-title":"Cell Rep"},{"issue":"12","key":"2025081304271013000_luaf160-B3","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1093\/annonc\/mdz400","article-title":"Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2020","volume":"30","author":"Filetti","year":"2019","journal-title":"Ann Oncol"},{"issue":"4","key":"2025081304271013000_luaf160-B4","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.annonc.2021.12.014","article-title":"Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study","volume":"33","author":"Subbiah","year":"2022","journal-title":"Ann Oncol"},{"key":"2025081304271013000_luaf160-B5","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ejca.2022.12.002","article-title":"Current picture of anaplastic thyroid cancer patients' care and meetable needs: a survey of 94 institutions from the EORTC endocrine and head and neck cancer groups","volume":"180","author":"Locati","year":"2023","journal-title":"Eur J Cancer"},{"issue":"23","key":"2025081304271013000_luaf160-B6","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1200\/JCO.19.02727","article-title":"PD-1 Blockade in anaplastic thyroid carcinoma","volume":"38","author":"Capdevila","year":"2020","journal-title":"J Clin Oncol"},{"issue":"8","key":"2025081304271013000_luaf160-B7","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1089\/thy.2022.0073","article-title":"An evaluation of clinical efficacy of immune checkpoint inhibitors for patients with anaplastic thyroid carcinoma","volume":"32","author":"Hatashima","year":"2022","journal-title":"Thyroid"},{"issue":"15_suppl","key":"2025081304271013000_luaf160-B8","doi-asserted-by":"crossref","first-page":"6513","DOI":"10.1200\/JCO.2020.38.15_suppl.6513","article-title":"A phase II study of nivolumab (N) plus ipilimumab (I) in radioidine refractory differentiated thyroid cancer (RAIR DTC) with exploratory cohorts in anaplastic (ATC) and medullary thyroid cancer (MTC)","volume":"38","author":"Lorch","year":"2020","journal-title":"JCO"},{"issue":"12","key":"2025081304271013000_luaf160-B9","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1001\/jamaoncol.2024.4729","article-title":"Anti-programmed death ligand 1 plus targeted therapy in anaplastic thyroid carcinoma: a nonrandomized clinical trial","volume":"10","author":"Cabanillas","year":"2024","journal-title":"JAMA Oncol"},{"issue":"11","key":"2025081304271013000_luaf160-B10","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1089\/thy.2019.0086","article-title":"A phase 2 study of pembrolizumab combined with chemoradiotherapy as initial treatment for anaplastic thyroid cancer","volume":"29","author":"Chintakuntlawar","year":"2019","journal-title":"Thyroid"},{"key":"2025081304271013000_luaf160-B11","doi-asserted-by":"crossref","first-page":"107067","DOI":"10.1016\/j.oraloncology.2024.107067","article-title":"Combination kinase inhibitors and immunotherapy for unresectable anaplastic thyroid carcinoma: a retrospective single-center study","volume":"159","author":"Song","year":"2024","journal-title":"Oral Oncol"},{"issue":"7","key":"2025081304271013000_luaf160-B12","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1089\/thy.2020.0322","article-title":"Combination of lenvatinib and pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma","volume":"31","author":"Dierks","year":"2021","journal-title":"Thyroid"},{"issue":"1","key":"2025081304271013000_luaf160-B13","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12902-024-01555-y","article-title":"First effectiveness data of lenvatinib and pembrolizumab as first-line therapy in advanced anaplastic thyroid cancer: a retrospective cohort study","volume":"24","author":"Soll","year":"2024","journal-title":"BMC Endocr Disord"},{"key":"2025081304271013000_luaf160-B14","doi-asserted-by":"crossref","first-page":"S1085","DOI":"10.1016\/j.annonc.2020.08.1403","article-title":"1915P the lenvatinib\/pembrolizumab combination induces long lasting and complete responses in patients with metastatic anaplastic or poorly differentiated thyroid carcinoma: results from a retrospective study and first results from the prospective phase II ATLEP trial","volume":"31","author":"Dierks","year":"2020","journal-title":"Ann Oncol"},{"issue":"1","key":"2025081304271013000_luaf160-B15","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s40425-018-0378-y","article-title":"Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma","volume":"6","author":"Iyer","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"12","key":"2025081304271013000_luaf160-B16","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1001\/jamaoncol.2024.4019","article-title":"Dual immune checkpoint inhibition in patients with aggressive thyroid carcinoma: a phase 2 nonrandomized clinical trial","volume":"10","author":"Sehgal","year":"2024","journal-title":"JAMA Oncol"},{"issue":"6","key":"2025081304271013000_luaf160-B17","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1200\/JOP.2016.012013","article-title":"Anaplastic thyroid carcinoma: treatment in the age of molecular targeted therapy","volume":"12","author":"Cabanillas","year":"2016","journal-title":"JOP"},{"issue":"15_suppl","key":"2025081304271013000_luaf160-B18","doi-asserted-by":"crossref","first-page":"e18114","DOI":"10.1200\/JCO.2018.36.15_suppl.e18114","article-title":"Relationship of anaplastic thyroid cancer high tumor mutation burden and MSI-H status with response to anti-PD1 monotherapy","volume":"36","author":"Khan","year":"2018","journal-title":"JCO"},{"issue":"10","key":"2025081304271013000_luaf160-B19","doi-asserted-by":"crossref","first-page":"7718","DOI":"10.3390\/curroncol29100610","article-title":"Rationale efficacy and safety evidence of lenvatinib and pembrolizumab association in anaplastic thyroid carcinoma","volume":"29","author":"Boudin","year":"2022","journal-title":"Curr Oncol"},{"issue":"6","key":"2025081304271013000_luaf160-B20","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2217\/fon-2020-0937","article-title":"The LEAP program: lenvatinib plus pembrolizumab for the treatment of advanced solid tumors","volume":"17","author":"Taylor","year":"2021","journal-title":"Future Oncol"},{"issue":"3","key":"2025081304271013000_luaf160-B21","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1089\/thy.2023.0573","article-title":"Checkpoint inhibition in addition to dabrafenib\/trametinib for BRAFV600E-mutated anaplastic thyroid carcinoma","volume":"34","author":"Hamidi","year":"2024","journal-title":"Thyroid"},{"issue":"5","key":"2025081304271013000_luaf160-B22","doi-asserted-by":"crossref","first-page":"57","DOI":"10.21037\/cco-23-55","article-title":"Boosted abscopal effect from radiotherapy and pembrolizumab in anaplastic thyroid cancer: a mini-review and case report","volume":"12","author":"Goh","year":"2023","journal-title":"Chin Clin Oncol"},{"issue":"5","key":"2025081304271013000_luaf160-B23","first-page":"299","article-title":"Anaplastic thyroid cancer successfully treated with radiation and immunotherapy: a case report","volume":"7","author":"Yang","year":"2021","journal-title":"AACE Clin Case Rep"},{"key":"2025081304271013000_luaf160-B24","doi-asserted-by":"crossref","first-page":"1125226","DOI":"10.3389\/fonc.2023.1125226","article-title":"Radiotherapy combined with immunotherapy successfully treated one case of anaplastic thyroid cancer: a case report","volume":"13","author":"Xing","year":"2023","journal-title":"Front Oncol"},{"issue":"5","key":"2025081304271013000_luaf160-B25","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nrc.2018.6","article-title":"Using immunotherapy to boost the abscopal effect","volume":"18","author":"Ngwa","year":"2018","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"2025081304271013000_luaf160-B26","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/annonc\/mdy551","article-title":"Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors","volume":"30","author":"Heinhuis","year":"2019","journal-title":"Ann Oncol"}],"container-title":["JCEM Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/3\/9\/luaf160\/63858972\/luaf160.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/3\/9\/luaf160\/63858972\/luaf160.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T08:27:22Z","timestamp":1755073642000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcemcr\/article\/doi\/10.1210\/jcemcr\/luaf160\/8214514"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,17]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,7,17]]}},"URL":"https:\/\/doi.org\/10.1210\/jcemcr\/luaf160","relation":{},"ISSN":["2755-1520"],"issn-type":[{"value":"2755-1520","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,7,17]]},"article-number":"luaf160"}}